Taking Medicines Back to The Future – A Discussion with Hedley Rees on Value Chain vs. Supply Chain: What’s the Difference?

Hey Google, tell me about the importance of living Development Reports with Kyriakos Michailaros
October 9, 2020
A Discussion on CMC Strategy and Submissions with Ed Narke, Brian Lihou & Meranda Parascandola
October 23, 2020

Taking Medicines Back to The Future – A Discussion with Hedley Rees on Value Chain vs. Supply Chain: What’s the Difference?

Episode Summary

Hedley Rees is a Managing Consultant at PharmaFlow Limited, a UK based consultancy specializing in operations and supply chain management within the life science sector. Throughout his career, Hedley realized that there was and continues to be something seriously wrong with how medicine has come to market. As such, he has been a passionate advocate of modernization in the pharma and biotech industries. Hedley is also the author of Taming the Big Pharma Monster By Speaking Truth to Power and Supply Chain Management in the Drug Industry. In this episode, Hedley, Ed, Meranda and Brian discuss value chain, quality by design (QBD) and ongoing issues in the pharmaceutical industry.

What We Covered

  • 00:59 – Hedley Rees joins the show to share his background in the pharmaceutical industry, his thoughts on Big Pharma and issues he’s observed with medicine coming to market
  • 09:43 – Hedley speaks to the importance of designing supply chains strategically and why your supply chain is actually your value chain
  • 17:51 – Hedley discusses outsourcing in the pharmaceutical industry
  • 24:07 – Hedley provides his thoughts on Quality by Design (QBD), including changes that must be made to the process
  • 39:22 – Hedley shares some of his upcoming projects
  • 42:27 – Ed, Brian and Meranda thank Hedley for joining the show

Tweetable Quotes

If they all beat together at the same time, instead of taking sixteen years for penicillin to come to market it would take maybe four years. Click To Tweet The main point between strategic supply team management is you actually engage with the end user of your product the same way as Apple would or any company who really builds value into their products. Click To Tweet The value that you add – the money you bring in – has got to be less than the cost that you incur in the business and then you obviously make a profit grow. Click To Tweet In terms of procurement, the industry has outsourced this critical asset. Click To Tweet The problem with pharma is that there is no competition because once you’ve got a patented molecule approved, the most that’s gonna happen is you get an oligopoly where two or three companies make blockbuster revenue. Click To Tweet The body is the most complex, connected thing in the world. Click To Tweet The other thing that people have noticed is that you can develop a drug now without being a pharma company. Click To Tweet

Links Mentioned

Design Space InPharmatics – LinkedIn

Design Space InPharmatics – Twitter

Edward Narke on LinkedIn

Hedley Rees on LinkedIn

Hedley’s Book – Taming the Big Pharma Monster By Speaking Truth to Power

Hedley’s Blog PharmaFlow

Cutting Through the QBD Foliage, Aiming for the Roots Article